Sotorasib

Generic Name
Sotorasib
Brand Names
Lumakras, Lumykras
Drug Type
Small Molecule
Chemical Formula
C30H30F2N6O3
CAS Number
2252403-56-6
Unique Ingredient Identifier
2B2VM6UC8G
Background

Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS mutations. Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s. It is the first expe...

Indication

Sotorasib is indicated in the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received at least one prior systemic therapy.

Associated Conditions
Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Associated Therapies
-
Clinical Trials
Related News

Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
Drug: Sotorasib
First Posted Date
2021-05-14
Last Posted Date
2024-04-19
Lead Sponsor
Amgen
Target Recruit Count
20
Registration Number
NCT04887064
Locations
🇺🇸

Pinnacle Clinical Research - San Antonio, San Antonio, Texas, United States

🇺🇸

Orange County Research Center, Tustin, California, United States

🇺🇸

American Research Corporation, San Antonio, Texas, United States

and more 2 locations

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

First Posted Date
2021-01-22
Last Posted Date
2023-05-18
Lead Sponsor
Jacobio Pharmaceuticals Co., Ltd.
Target Recruit Count
200
Registration Number
NCT04720976
Locations
🇺🇸

Research Site, Salt Lake City, Utah, United States

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

First Posted Date
2020-11-12
Last Posted Date
2024-06-11
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
116
Registration Number
NCT04625647
Locations
🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States

🇺🇸

Southwest Oncology PC, Durango, Colorado, United States

and more 707 locations

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

First Posted Date
2019-12-04
Last Posted Date
2024-11-28
Lead Sponsor
Amgen
Target Recruit Count
1200
Registration Number
NCT04185883
Locations
🇺🇸

Henry Ford Cancer Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan, United States

🇺🇸

Arizona Oncology Associates Professional Corporation, Tucson, Arizona, United States

🇺🇸

City of Hope National Medical Center, Duarte, California, United States

and more 87 locations

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

First Posted Date
2019-09-17
Last Posted Date
2024-05-21
Lead Sponsor
Effector Therapeutics
Target Recruit Count
30
Registration Number
NCT04092673
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center- Westchester, Harrison, New York, United States

🇺🇸

Stanford University, Palo Alto, California, United States

🇺🇸

START Midwest, Grand Rapids, Michigan, United States

and more 11 locations

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

First Posted Date
2018-07-26
Last Posted Date
2024-10-04
Lead Sponsor
Amgen
Target Recruit Count
713
Registration Number
NCT03600883
Locations
🇺🇸

Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

Gibbs Cancer Center and Research Institute - Spartanburg, Spartanburg, South Carolina, United States

and more 130 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy